National Pregnancy Registry for Atypical Antipsychotics

The National Pregnancy Registry for Atypical Antipsychotics is dedicated to evaluating the
safety of atypical antipsychotic medications that may be taken by women during pregnancy to
treat a wide range of mood, anxiety, or psychiatric disorders. The primary goal of this
Registry is to determine the frequency of major malformations, such as heart defects, cleft
lip, or neural tube defects, in infants exposed to atypical antipsychotics during pregnancy.
We are currently studying the following medications:

- Abilify (aripiprazole)

- Aristada (aripiprazole lauroxil)

- Clozaril (clozapine)

- Fanapt (iloperidone)

- Geodon (ziprasidone)

- Invega (paliperidone)

- Latuda (lurasidone)

- Rexulti (brexpiprazole)

- Risperdal (risperidone)

- Saphris (asenapine)

- Seroquel (quetiapine)

- Zyprexa (olanzapine)

Inclusion Criteria:

- Pregnant women

- Age 18-45

- Currently taking or have taken an atypical antipsychotic during pregnancy (or for
internal control, women not exposed to atypical antipsychotics)

- Subjects will be willing to participate over the phone

- Subjects will be able to provide informed consent

Exclusion Criteria:

- Women who have completed their pregnancy

- Women who are planning to become pregnant